Personalised and actionable, based on your tumour genetics.
Your tumour has been sequenced. Somewhere in your file is a page listing the genes that are mutated in it, and in most cases nobody has explained what any of it means.
Send me that page and I will write you a plan: what each finding does inside a cell, which ones matter, what the evidence supports doing alongside your treatment, and what to avoid because it would work against it.
A flat 50$ for a limited time, and I sent you the report as a PDF within a week.
I am a molecular biologist with a Ph.D., a research scientist, and a colorectal cancer patient. I am not a doctor. The plan explains biology and published evidence. It is not medical advice, and it never tells you to start, stop or change a treatment. It is written to be taken to your oncologist.
What I cover: cancer genomics, the microbiome, diet, exercise and supplements. Prognosis, imaging, surgery and drug dosing are outside it, and I will say so rather than guess.
Why my book is not enough
I wrote a book about what helps alongside colorectal cancer treatment and I stand behind it. But a book is an average: a trial reports what happened across several hundred people with several hundred different tumours. In places mine is also shaped by my own genotype, because I was the patient I had most data on.
You are not that average. Aspirin has about as much evidence behind it as anything in this field, and whether it helps you depends on your tumour. Whether it is safe depends on your clotting, your stomach, your kidneys and what else you take. Two people with the same diagnosis can get opposite answers, and both are right.
A supplement that helps one person can harm another. The excerpt below is a real case: three sold as general support for people with cancer, all of which would have undermined the most useful weakness in my own tumour. Nothing on the label could have told me that.
Read the book for the general case. Buy this to find out which parts of it apply to you.
What you get
Three things the book cannot do.
Your genotype, in much more depth
What your mutations do to a cell, what they make it depend on, and which ideas from the book become promising or pointless for you. With germline data, how you process drugs and supplements, which often separates a sensible dose from a harmful one.
A plan for where you are now
In remission, the aim is preventing recurrence with something you can keep up for years. On treatment, the first question about anything is whether it interferes with what you are having, because several well-regarded supplements do. Newly diagnosed, it is about what your profile means for the choices in front of you. Nothing in it ever asks you to skip a dose.
An escalation plan
If a marker rises or something shows on a scan, that is the worst moment to start reading research. So it is mapped in advance, in levels: what becomes worth considering, what to ask, and which trials and treatments your profile would make you a candidate for.
An excerpt, from my own
The first plan of this kind I wrote was for myself, after my own diagnosis, because I wanted to know what my sequencing meant and nobody was going to tell me. Here are a few paragraphs, with the parts that identify me taken out.
Section 1: your molecular fingerprint
Most colorectal cancers follow a standard sequence of mutations: APC, then KRAS, then TP53. Your tumour departs from that pattern in six ways, and each departure is something that can be used.
2. Loss of ARID1A, in every tumour cell. ARID1A is part of the machinery that decides which genes a cell can read. One gene it is needed for builds the transporter that imports cystine, the raw material for glutathione, which is how a cell protects its own membranes from damage.
So your tumour cells are chronically short of glutathione in a way your healthy cells are not. That leaves them vulnerable to ferroptosis, a form of cell death where iron drives a chain reaction through the fats in a membrane until it fails. Healthy cells have enough glutathione to stop that reaction. These do not, which shapes much of this plan: it is a weakness worth pressing, and one that ordinary supplements can undo.
Section 4: supplements to avoid
| Avoid | Why, for your tumour |
|---|---|
| N-acetylcysteine, glutathione, alpha-lipoic acid | All three supply exactly what the ARID1A mutation has made the tumour short of, handing back the weakness this plan is built around. Sold as liver support. For you, counterproductive. |
| High-dose vitamin E or selenium | Strong blockers of the chain reaction above; protect the cells you least want protected. |
| Standard multivitamins | Synthetic folic acid, which your metabolism handles poorly. Selenium, which arms the enzyme that defends against the mechanism above. Copper, which a KRAS-mutant cell needs for its main growth signal. |
Section 5: the escalation plan
| Level | Trigger | What it holds |
|---|---|---|
| 1, now | No evidence of disease | The daily plan built on the weaknesses in Section 1, and the blood tests that would give the earliest warning. |
| 2, early warning | A marker rising across two draws, or ctDNA turning positive, while scans are clear | Measurable but not yet visible, which is where most is gained. What to intensify, and what to raise with your team straight away. |
| 3, recurrence | Something visible on imaging | Treatments and trials this profile matches, entry criteria already checked, so the conversation starts from a shortlist. |
Every line of Levels 2 and 3 is a conversation to have with your oncologist. The full plan runs to about thirty pages, with a daily schedule, what to monitor, and the references.
What to send
How good your plan can be depends on how many genes were looked at, because nobody can write about a gene that was never tested. Send the most comprehensive thing you have and I will tell you what it supports before you pay anything.
Best: a comprehensive tumour panel such as Oncomine, FoundationOne, Caris, TruSight Oncology 500 or Guardant360, or whole genome or whole exome sequencing. Hundreds of genes, usually with copy number and microsatellite status.
Good: your first Signatera report, which lists the variants it tracks. A lot of people have one without realising it is useful here. A smaller hospital panel covering RAS, BRAF, MMR or MSI and HER2 also works, because in colorectal cancer those few genes decide a great deal.
Still worth sending: anything. A pathology report gives stage, grade and margins. A 23andMe or AncestryDNA file is not a tumour test, but it says how you metabolise drugs and supplements, which is most of the safety half. If you have both, send both.
Not sure what you have? Send the paperwork and I will work out what it is. If nothing has been sequenced, ask your oncologist whether profiling has been done. In many places it is routine and the result may already be in your file.
Price, and how it works
A flat [crc_report_price], whatever your situation turns out to involve. It is an opening price and a low one, because this is new and I would rather find out what it is worth by doing it. It will go up.
- You send your genetics with the form below. Nothing is charged and you are committed to nothing.
- I write back within a couple of days saying how much of a plan it supports. If there is not enough to be worth paying for, you have lost nothing.
- If it is worth doing, that email has a payment link.
- The PDF arrives within a week, usually sooner. If anything is unclear, ask, and that is included.
Your documents go to my own inbox and nowhere else. They are deleted from this website as the email is sent, nothing is kept here, and I will never share them with anyone.
Send me your genetics
Only the starred fields are needed. The one I will press you on is what you currently take, because the section on what to avoid is written against it.
[crc_report_form]